Skip to content
buyNotable cluster of 3

Thomas Von Koch bought $3.5M of DMAC

owner at DiaMedica Therapeutics Inc.. 2,855,847 shares at an average of $1.24, traded Dec 2, 2022, filed Dec 6, 2022.

Conviction score
63
Value
$3.5M
2,855,847 shares
Holdings after
2,855,847
change unknown
From 52-week low
+31%
low $1.13, close $1.48
From 52-week high
-62%
high $3.90, as of Dec 2, 2022

Score components

  • Role
    10% owner
    +12
  • Trade size
    $3.5M at market
    +25
  • Relative to holdings
    First purchase: no shares before this trade
    +8
  • Price context
    62% below the 52-week high
    +8
  • Cluster
    3 insiders buying within 14 days
    +15
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (2 with prices)
    0
  • Outside holder
    A 10% owner who is not an officer or director
    -5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

DMACOct 13, 2026 · close 7.82
Since filing Dec 6, 2022: +450.7%SPY +108.1% · excess +342.6%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001567619-22-021344, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 2, 2022SOpen-market sale
Common Sharesindirect: See Footnote 1
-2,855,847$1.24$3.5M0Dec 6, 2022
Dec 2, 2022POpen-market purchase
Common Sharesindirect: See Footnote 2
+2,855,847$1.24$3.5M2,855,847Dec 6, 2022

Related signals

Other insiders at DiaMedica Therapeutics Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
35Weak
DMACbuy
DiaMedica Therapeutics Inc.
Jan Stahlberg
owner
$7.6M
1,061,277 shares
+14%
40Moderate
DMACbuy
DiaMedica Therapeutics Inc.
Jan Stahlberg
owner
$6.0M
1,000,000 shares
+15%
57Moderate
DMACbuy 3
DiaMedica Therapeutics Inc.
Thomas Von Koch
owner
$10.0M
2,857,142 shares
+52%
53Moderate
DMACbuy 3
DiaMedica Therapeutics Inc.
Jan Stahlberg
owner
$5.4M
1,542,857 shares
+30%
50Moderate
DMACbuy 3
DiaMedica Therapeutics Inc.
Richard Jacinto II
owner
$1.4M
400,000 shares
+9%
64Notable
DMACbuy 2
DiaMedica Therapeutics Inc.
Jan Stahlberg
owner
$3.0M
1,200,000 shares
+30%
54Moderate
DMACbuy 2
DiaMedica Therapeutics Inc.
Thomas Von Koch
owner
$3.0M
1,200,000 shares
+28%
30Weak
DMACbuy
DiaMedica Therapeutics Inc.
David J. Wambeke
Chief Business Officer
$49k
20,000 shares
+4%
58Moderate
DMACbuy 3
DiaMedica Therapeutics Inc.
Randall Michael Giuffre
director
$81k
57,079 shares
+28%
52Moderate
DMACbuy 3
DiaMedica Therapeutics Inc.
Randall Michael Giuffre
director
$35k
24,874 shares
+14%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Thomas Von Koch bought $3.5M of DMAC | InsiderTell